Phase I/II Trial Approval for Delta-Fly Pharma's DFP-10917 and Venetoclax Combination

Delta-Fly Pharma, Inc. is a pharmaceutical company that has recently made significant strides in the field of oncology. The company has been working on a Phase I/II clinical trial involving a drug combination therapy for acute myeloid leukemia (AML). This trial pairs DFP-10917 with Venetoclax (VTX), targeting patients who have previously undergone a VTX-containing treatment regimen. The trial protocol was submitted to the FDA on March 8th and received approval on April 8th, 2024, paving the way for the imminent commencement of the study.

The primary objective of this research is to determine the efficacy of the DFP-10917 and VTX combination against the standard chemotherapy treatment, which typically involves azacitidine in conjunction with VTX. The study will be conducted at prominent clinical sites in the United States, with Wake Forest University taking a leading role due to its expertise in novel chemotherapy treatments for AML.

In addition to the Phase I/II trial, Delta-Fly Pharma is also monitoring the outcomes of a Phase III trial focusing on DFP-10917 as a monotherapy for patients with recurrent or refractory AML. This study is particularly interested in the long-term survival of a subset of participants, as their outcomes could significantly influence the overall survival analysis.

The company is dedicated to pioneering new approaches for cancer patients who are in dire need of innovative treatments. Their commitment to advancing cancer care is evident through their ongoing clinical trials and research efforts. Delta-Fly Pharma's work holds promise for improving the lives of those affected by AML and potentially revolutionizing the way this disease is treated.